EP1137340A4 - Zusammensetzung und verfahren zur regulation des körpergewichtes und damit zusammenhängender zustände - Google Patents

Zusammensetzung und verfahren zur regulation des körpergewichtes und damit zusammenhängender zustände

Info

Publication number
EP1137340A4
EP1137340A4 EP99965208A EP99965208A EP1137340A4 EP 1137340 A4 EP1137340 A4 EP 1137340A4 EP 99965208 A EP99965208 A EP 99965208A EP 99965208 A EP99965208 A EP 99965208A EP 1137340 A4 EP1137340 A4 EP 1137340A4
Authority
EP
European Patent Office
Prior art keywords
regulation
composition
body weight
associated conditions
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP99965208A
Other languages
English (en)
French (fr)
Other versions
EP1137340A1 (de
Inventor
Miles B Brennan
Ute Hochgeschwender
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roosevelt Eleanor Institute for Cancer Research Inc
Oklahoma Medical Research Foundation
Original Assignee
Roosevelt Eleanor Institute for Cancer Research Inc
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/374,827 external-priority patent/US6603058B1/en
Application filed by Roosevelt Eleanor Institute for Cancer Research Inc, Oklahoma Medical Research Foundation filed Critical Roosevelt Eleanor Institute for Cancer Research Inc
Publication of EP1137340A1 publication Critical patent/EP1137340A1/de
Publication of EP1137340A4 publication Critical patent/EP1137340A4/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP99965208A 1998-12-09 1999-12-09 Zusammensetzung und verfahren zur regulation des körpergewichtes und damit zusammenhängender zustände Ceased EP1137340A4 (de)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US11158198P 1998-12-09 1998-12-09
US111581P 1998-12-09
US14629999P 1999-07-29 1999-07-29
US14630499P 1999-07-29 1999-07-29
US14630199P 1999-07-29 1999-07-29
US14630399P 1999-07-29 1999-07-29
US14630599P 1999-07-29 1999-07-29
US14630299P 1999-07-29 1999-07-29
US14630699P 1999-07-29 1999-07-29
US14630099P 1999-07-29 1999-07-29
US146304P 1999-07-29
US146302P 1999-07-29
US146306P 1999-07-29
US146300P 1999-07-29
US146301P 1999-07-29
US146299P 1999-07-29
US146305P 1999-07-29
US146303P 1999-07-29
US374827 1999-08-12
US09/374,827 US6603058B1 (en) 1998-12-09 1999-08-12 Non-human animal model for obesity and uses thereof
PCT/US1999/029337 WO2000033658A1 (en) 1998-12-09 1999-12-09 Composition and method for regulation of body weight and associated conditions

Publications (2)

Publication Number Publication Date
EP1137340A1 EP1137340A1 (de) 2001-10-04
EP1137340A4 true EP1137340A4 (de) 2005-12-21

Family

ID=27581011

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99965208A Ceased EP1137340A4 (de) 1998-12-09 1999-12-09 Zusammensetzung und verfahren zur regulation des körpergewichtes und damit zusammenhängender zustände

Country Status (6)

Country Link
EP (1) EP1137340A4 (de)
JP (1) JP2003520015A (de)
AU (1) AU3117600A (de)
CA (1) CA2353776A1 (de)
MX (1) MXPA01005818A (de)
WO (1) WO2000033658A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2406755A1 (en) * 2000-04-28 2001-11-08 Zengen Inc. A gene therapy system and method using alpha-msh and its derivatives
EP1303625A2 (de) 2000-07-14 2003-04-23 Zycos Inc. Alpha-msh-verwandte verbindungen und verfahren zur verwendung davon
EP1322954A4 (de) * 2000-09-13 2005-08-03 Eleanor Roosevelt Inst Verfahren zur behandlung von insulinresistenz bei übergewichtigkeit und diabetes
AU2002238106A1 (en) 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US20060293223A1 (en) * 2003-06-19 2006-12-28 Eli Lilly And Company Patent Division Uses of melanocortin-3 receptor (mc3r) agonist peptides
KR20060014444A (ko) * 2003-06-19 2006-02-15 일라이 릴리 앤드 캄파니 멜라노코르틴 수용체 4 (ｍｃ4) 작용제 및 그의 용도
FR2857873B1 (fr) * 2003-07-21 2006-02-24 Courtage Et De Diffusion Codif Procede et produit cosmetique destines a limiter la croissance des tissus adipeux
US20070123453A1 (en) * 2004-03-29 2007-05-31 Heiman Mark L Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion
US7741085B2 (en) * 2004-04-08 2010-06-22 Astellas Pharma Inc. Compound WS727713
WO2005118573A1 (en) 2004-05-28 2005-12-15 Smithkline Beecham Corporation Novel diazepine compounds as ligands of the melanocortin 1 and/or 4 receptors
US7169773B2 (en) 2004-07-01 2007-01-30 Smithkline Beecham Corporation Compounds
US7910101B2 (en) 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
CN101437540B (zh) * 2004-10-25 2012-12-19 森托科尔公司 结合黑皮质素受体的拟抗体、组合物、方法和用途
WO2006073771A2 (en) * 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
US7790671B2 (en) 2005-10-07 2010-09-07 Codman & Shurtleff, Inc. Implantable pump for protein delivery for obesity control by drug infusion into the brain
KR20110028457A (ko) 2008-05-21 2011-03-18 뉴로테즈 인코포레이티드 신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법
AU2009313562B2 (en) 2008-11-04 2012-11-15 Neurotez, Inc. Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010068A2 (en) * 1996-09-04 1998-03-12 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932779A (en) * 1996-06-10 1999-08-03 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010068A2 (en) * 1996-09-04 1998-03-12 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"A FRAMESHIFT MUTATION IN HUMAN MC4R IS ASSOCIATED WITH A DOMINANT FORM OF OBESITY", NATURE GENETICS, NEW YORK, NY, US, vol. 20, no. 2, October 1998 (1998-10-01), pages 113 - 114, XP000866527, ISSN: 1061-4036 *
"A FRAMESHIFT MUTATION IN MC4R ASSOCIATED WITH DOMINANTLY INHERITED HUMAN OBESITY", NATURE GENETICS, NEW YORK, NY, US, vol. 20, no. 2, October 1998 (1998-10-01), pages 111 - 112, XP000866528, ISSN: 1061-4036 *
BERTAGNA XAVIER: "Proopiomelanocortin-derived peptides", ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, vol. 23, no. 3, 1994, pages 467 - 485, XP009046900, ISSN: 0889-8529 *
BOSTON BRUCE A ET AL: "Characterization of melanocortin receptor subtype expression in murine adipose tissues and in the 3T3-L1 cell line", ENDOCRINOLOGY, vol. 137, no. 5, 1996, pages 2043 - 2050, XP002326390, ISSN: 0013-7227 *
CHAGNON YVON C ET AL: "Linkage and association studies between the melanocortin receptors 4 and 5 genes and obesity-related phenotypes in the Quebec Family Study", MOLECULAR MEDICINE (NEW YORK), vol. 3, no. 10, October 1997 (1997-10-01), pages 663 - 673, XP009046979, ISSN: 1076-1551 *
CHEUNG C C ET AL: "PROOPIOMELANOCORTIN NEURONS ARE DIRECT TARGETS FOR LEPTIN IN THE HYPOTHALAMUS", ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 138, no. 10, 1997, pages 4489 - 4492, XP009027762, ISSN: 0013-7227 *
FAN W ET AL: "ROLE OF MELANOCORTINERGIC NEURONS IN FEEDING AND THE AGOUTI OBESITY SYNDROME", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 385, 9 January 1997 (1997-01-09), pages 165 - 168, XP002072475, ISSN: 0028-0836 *
HUSZAR D ET AL: "TARGETED DISRUPTION OF THE MELANOCORTIN-4 RECEPTOR RESULTS IN OBESITY IN MICE", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 88, no. 1, 10 January 1997 (1997-01-10), pages 131 - 141, XP000877328, ISSN: 0092-8674 *
JACKSON R S ET AL: "Proopiomelanocortin products and human early-onset obesity.", THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM. FEB 1999, vol. 84, no. 2, February 1999 (1999-02-01), pages 819 - 820, XP002326389, ISSN: 0021-972X *
MIZUNO T M ET AL: "HYPOTHALAMIC PRO-OPIOMELANOCORTIN MRNA IS REDUCED BY FASTING IN OB/OB AND DB/DB MICE, BUT IS STIMULATED BY LEPTIN", DIABETES, NEW YORK, NY, US, vol. 47, no. 2, February 1998 (1998-02-01), pages 294 - 297, XP001063909, ISSN: 0012-1797 *
POGGIOLI R ET AL: "ACTH-(1-24) and alpha-MSH antagonize feeding behaviour stimulated by kappa opiate antagonists", PEPTIDES, ELSEVIER, AMSTERDAM, US, vol. 7, no. 5, 1986, pages 843 - 848, XP009018115, ISSN: 0196-9781 *
See also references of WO0033658A1 *

Also Published As

Publication number Publication date
AU3117600A (en) 2000-06-26
EP1137340A1 (de) 2001-10-04
MXPA01005818A (es) 2003-07-21
CA2353776A1 (en) 2000-06-15
WO2000033658A1 (en) 2000-06-15
JP2003520015A (ja) 2003-07-02

Similar Documents

Publication Publication Date Title
EP1137340A4 (de) Zusammensetzung und verfahren zur regulation des körpergewichtes und damit zusammenhängender zustände
ZA9711421B (en) Method and compositions for weight control
ZA989875B (en) Composition and method for inhibiting the growth of microorganisms including stabilized sodium hypbromite and isothiazolones
PL336326A1 (en) Method of and composition for treating sleep apnoea
EP1143987A4 (de) Natürliche zusammensetzung und methode zur behandlung von sexuellen dysfunktionen
EP1027045A4 (de) Methoden und zusammenstellungen zur regelierung des s-alpha-reduktaseaktivität
EP0918787A4 (de) Zusammensetzungen und methoden zur gegenstrang-hemmung der proteinübersetzung
PL337531A1 (en) Compositions for and methods of inhibiting photo-ageing of skin
PL352014A1 (en) Dietetic of pharmacological composition for preventing or treating hyperoxaluria
GB9422571D0 (en) Haemorrihoidal compositions and method of use
PL336466A1 (en) Composition for and method of fighting against harmful bio-organisms
PL329893A1 (en) Method of and compositions for treating and preventing hyperuricaemia
AU7755398A (en) Method for reducing body weight
ZA964562B (en) Antipsychotic agents compositions and method of use
GB9814733D0 (en) Method of reducing or preventing malodour
GB9927191D0 (en) Methods and means for regulation of gene expression
EP0915706A4 (de) Untersuchungsmethoden für verbindungen die das körpergewicht regulieren können
IL120128A0 (en) Compositions for the treatment of androgenetic alopecia and hirsutism
HUP9801629A3 (en) Methods and compositions for regulation of cd28 expression
GB9814732D0 (en) Method of reducing or preventing malodour
GB2351976B (en) Mastic composition and method of preparing same
EP1096927A4 (de) Zusammensetzung für stressbehandlung
HU9302099D0 (en) Method and composition for improving increase of weight of pigs
HK1037139A1 (en) Novel uses of ascorbyl-phosphoryl-cholesterol and compositions for practicing same
HUP9900436A3 (en) Installation and method for the treatment of wine-production efilvents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010704

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 43/00 B

Ipc: 7A 61P 25/00 B

Ipc: 7A 61P 3/04 B

Ipc: 7A 61K 38/03 B

Ipc: 7A 01K 67/027 B

Ipc: 7G 01N 33/00 A

A4 Supplementary search report drawn up and despatched

Effective date: 20051107

17Q First examination report despatched

Effective date: 20070403

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20110718